SCHEMBL19096830

SCHEMBL19096830

COc1ccc(CN(CC2(O)CCN(C(=O)OC(C)(C)C)CC2)C(=O)C(C)Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.44
LMNA P02545 2/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 3/20 0.41
SLC2A1 P11166 1/20 0.41
KDM1A O60341 1/20 0.41
STS P08842 2/20 0.41
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BMP1 P13497 1/20 0.38
BACE1 P56817 2/20 0.38
CTSD P07339 1/20 0.38
CTSE P14091 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19096829 1.00 GPR119 (0.44) GPR119LMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL12492129 0.88 TSHR (0.42) GPR119LMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL18695987 0.87 GPR119 (0.41) GPR119LMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL13278067 0.77 GPR119 (0.48) GPR119LMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL13277786 0.76 ATM (0.43) GPR119LMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL32687398 0.76 CACNA1B (0.45) LMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL32687883 0.76 CACNA1B (0.45) LMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL19518220 0.76 USP2 (0.38) GPR119MAPTSMN1; SMN2ALDH1A1TSHR
SCHEMBL19518222 0.76 USP2 (0.38) GPR119MAPTSMN1; SMN2ALDH1A1TSHR
SCHEMBL30014880 0.76 USP2 (0.38) GPR119MAPTSMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10065971-B2 Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain ESTEVE PHARMACEUTICALS S.A. (ES) 2018-09-04 US disclosed
EP-3149005-B1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE LABOR DR (ES) 2018-04-18 EP disclosed
US-20170197984-A1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10065971-B2 Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain OPRD1, SIGMAR1, OPRM1 GPR119 328/4885LMNA 4163/4885MAPT 4178/4885
US-20170197984-A1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, SIGMAR1, OPRM1 GPR119 328/4885LMNA 4163/4885MAPT 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.